Drug news
TRV 027 fails Phase IIB BLAST-AHF study in acute heart failure.- Trevena
Trevena announced that the company’s TRV 027 failed to meet either the primary or secondary endpoints in the Phase IIb BLAST-AHF study in acute heart failure (AHF). Data from the BAST-AHF trial will be presented in a late-breaking trials session scheduled for 2:15-3:45pm CEST on Saturday, May 21 at Heart Failure 2016. The company expects to focus its efforts on its lead Phase III oliceridine pain program and its earlier stage programs.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.